Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12540513 | 1.00 | CYP17A1 (0.34) | CYP17A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2051194 | 0.89 | CYP17A1 (0.36) | CYP17A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2049567 | 0.84 | EIF4E (0.31) | — | |
| SCHEMBL2049570 | 0.84 | EIF4E (0.31) | — | |
| SCHEMBL2053070 | 0.83 | CYP17A1 (0.34) | CYP17A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2052006 | 0.80 | CYP17A1 (0.33) | CYP17A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12541094 | 0.77 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2032783 | 0.77 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2053190 | 0.74 | PSEN1 (0.43) | CYP17A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2053611 | 0.71 | EGLN2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859611-B2 | Thiophene inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2512247-B1 | NOVEL THIOPHENE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS INC (US) | 2014-06-04 | — | — | EP | disclosed |
| US-20140057957-A1 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8586624-B2 | Thiophene inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2512247-A1 | NOVEL THIOPHENE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 Pharmaceuticals, LLC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120245210-A1 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2011075478-A1 | NOVEL THIOPHENE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS, LLC (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057957-A1 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase | GSR, GRHPR, POR | CYP17A1 296/4885PSEN1 3720/4885PSEN2 3739/4885 |
| US-20120245210-A1 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase | GSR, GRHPR, POR | CYP17A1 296/4885PSEN1 3720/4885PSEN2 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.